The Pfizer Breakthrough Growth Initiative has been established with a $500 million investment.
Prellis Biologics Inc. generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.
Investment firm Blackstone Life Sciences and Alnylam Pharmaceuticals announced a broad strategic collaboration worth up to $2 billion.
Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases.
Astellas company Audentes Therapeutics announced construction of a gene therapy manufacturing plant in Sanford, North Carolina.
Eli Lilly will add 100 jobs to the company’s manufacturing facilities at the Lilly Technology Center campus in Indianapolis.
Thousand Oaks, California-based Amgen significantly expanded the company’s presence in China by taking a 20.5 percent stake in BeiGene Co.
Vir Biotechnology priced the company’s initial public offering (IPO) at $20 a share, at the bottom end of expectations, the latest underwhelming investment performance for a stock held by SoftBank Group Corp.’s Vision Fund.
Amphivena Therapeutics Inc., a private clinical stage immuno-oncology company developing T-cell engager therapeutics for cancer, announced the closing of a $62 million Series C financing.
A federal grand jury recently filed criminal charges against several developers for fraud involving a Vermont biotech company.
